Disseminated Cryptococcal Disease in a Patient With Monoclonal Gammopathy of Undetermined Significance and Polycythemia Vera: A Case Report and Review of the Literature

Cryptococcosis is a life-threatening opportunistic infection caused by Cryptococcus gattii and Cryptococcus neoformans. It affects both immunocompetent and immunosuppressed hosts. Disseminated cryptococcal infection is rare in immunocompetent patients, but the cryptococcal disease's neurological sequelae may be more prominent in this group. We present a case of a 58-year-old male patient with medical comorbidities of monoclonal gammopathy of undetermined significance (MGUS) and polycythemia vera. The patient presented with gradual worsening of mental status over one week. He was found to have Cryptococcus neoformans meningoencephalitis and fungemia. The patient received two weeks of liposomal amphotericin B (LAmB) and flucytosine with excellent clinical response. He was discharged on high dose fluconazole, and he returned to the hospital in one week with new-onset hemiplegia and cryptococcomas on imaging. Prolonged intravenous (IV) treatment of six weeks duration resulted in significant clinical improvement and disease-free state at two years follow-up. This article aims to stress the importance of individualized prolonged IV treatment with liposomal amphotericin B and flucytosine despite good initial response in patients with polycythemia vera and MGUS. This is the first reported case of cryptococcal disease, to the best of our knowledge, in a patient with MGUS and the third case of cryptococcal infection in patients with polycythemia vera in a non-HIV non-transplant state. Prolonged individualized IV treatment should be considered in immunocompetent patients with the above conditions, as this condition, if not adequately treated and relapses, lead to high morbidity and mortality.

[1]  D. Richman,et al.  A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib , 2019, BMC Infectious Diseases.

[2]  Z. Chagla,et al.  Disseminated Cryptococcal Disease in Non-HIV, Nontransplant Patient , 2016, Case reports in infectious diseases.

[3]  Chiung-Yu Huang,et al.  Cryptococcus Infection Network in Non-Human Immunodeficiency Virus Cohort (CINCH) Study: Initial Report of Treatment and Outcomes , 2016, Open forum infectious diseases.

[4]  S. Holland,et al.  Anti–GM-CSF Autoantibodies in Patients with Cryptococcal Meningitis , 2013, The Journal of Immunology.

[5]  J. Baddley,et al.  Predictors of Mortality and Differences in Clinical Features among Patients with Cryptococcosis According to Immune Status , 2013, PloS one.

[6]  S. Antinori New Insights into HIV/AIDS-Associated Cryptococcosis , 2013, ISRN AIDS.

[7]  J. Perfect,et al.  Comparison and Temporal Trends of Three Groups with Cryptococcosis: HIV-Infected, Solid Organ Transplant, and HIV-Negative/Non-Transplant , 2012, PloS one.

[8]  V. Yu,et al.  Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. , 2010, The Journal of infection.

[9]  J. Perfect,et al.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  L. Goldani,et al.  Histopathological Aspects of Neurocryptococcosis in HIV-Infected Patients: Autopsy Report of 45 Patients , 2009, International journal of surgical pathology.

[11]  I. Schmalfuss,et al.  The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  R. M. Warren,et al.  Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  S. Krähenbühl,et al.  Primary Cutaneous Cryptococcosis in aPatient with Systemic Immunosuppression after Liver Transplantation , 2000, Dermatology.

[14]  T. Sorrell,et al.  Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  A. Casadevall,et al.  Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  R. Diasio,et al.  Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. , 1987, The New England journal of medicine.

[17]  A. Forrestel,et al.  CRYPTOCOCCOSIS , 1982, The Lancet.

[18]  C. Kauffman,et al.  Detection of cryptococcal antigen. Comparison of two latex agglutination tests. , 1981, American journal of clinical pathology.